Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required.

Bauters, Tiene; Bordon, Victoria; Laureys, Geneviève; Dhooge, Catharina

Bauters, Tiene; Bordon, Victoria; Laureys, Geneviève; Dhooge, Catharina.

Afiliação

Bauters T; Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium. tiene.bauters@uzgent.be.
Bordon V; Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium.
Laureys G; Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium.
Dhooge C; Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium.

Bone Marrow Transplant ; 54(8): 1372-1373, 2019 08.

Article em En | MEDLINE | ID: mdl-30804487

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Hipertrigliceridemia/induzido quimicamente; Janus Quinases/efeitos adversos; Pirazóis/efeitos adversos; Sirolimo/efeitos adversos; Triglicerídeos/sangue; Humanos; Nitrilas; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Triglicerídeos / Hipertrigliceridemia / Protocolos de Quimioterapia Combinada Antineoplásica / Sirolimo / Janus Quinases Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google